PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications - PubMed (original) (raw)
PEG-functionalized magnetic nanoparticles for drug delivery and magnetic resonance imaging applications
Murali Mohan Yallapu et al. Pharm Res. 2010 Nov.
Abstract
Purpose: Polyethylene glycol (PEG) functionalized magnetic nanoparticles (MNPs) were tested as a drug carrier system, as a magnetic resonance imaging (MRI) agent, and for their ability to conjugate to an antibody.
Methods: An iron oxide core coated with oleic acid (OA) and then with OA-PEG forms a water-dispersible MNP formulation. Hydrophobic doxorubicin partitions into the OA layer for sustained drug delivery. The T(1) and T(2) MRI contrast properties were determined in vitro and the circulation of the MNPs was measured in mouse carotid arteries. An N-hydroxysuccinimide group (NHS) on the OA-PEG-80 was used to conjugate the amine functional group on antibodies for active targeting in the human MCF-7 breast cancer cell line.
Results: The optimized formulation had a mean hydrodynamic diameter of 184 nm with an ~8 nm iron-oxide core. The MNPs enhance the T(2) MRI contrast and have a long circulation time in vivo with 30% relative concentration 50 min post-injection. Doxorubicin-loaded MNPs showed sustained drug release and dose-dependent antiproliferative effects in vitro; the drug effect was enhanced with transferrin antibody-conjugated MNPs.
Conclusion: PEG-functionalized MNPs could be developed as a targeted drug delivery system and MRI contrast agent.
Figures
Figure 1
Magnetic nanoparticle synthesis (A) and layering of various OA-PEG polymers on the surface of the magnetic nanoparticles (B).
Figure 2
Magnetic nanoparticle size changes with OA-PEG polymer coating. (A) Mean particle size in water after modification with 25–300 mg of OE-20, OE-40, or OE-80 polymers. (B) Representative transmission electron micrograph of OE-40 polymer coated MNPs. Diameter of iron-oxide core ~8 nm.
Figure 3
Polymer modifications to OA-MNP core confirmed by (A) FTIR and (B) TGA.
Figure 4
X-ray photoelectron spectra with plain, OA, and OA and PEG-OE-80 coatings.
Figure 5
Macrophage uptake of particles with respect to iron level in protein. (Inset) Particle size in RPMI media (data is represented as mean ± SEM, n=3, *p<0.05 compared to Feridex IV).
Figure 6
Magnetic resonance imaging. (A) Contrast at varying iron concentrations for OA-PEG-MNPs and Feridex IV in agar gels. T2 relaxivity (B) and T1 relaxivity (C) for OE-80 MNPs. (Data as values obtained from curve fitting and standard errors are uncertainties in fitting.)
Figure 7
Calculated relative iron concentration vs. time profiles of magnetic nanoparticles in a mouse carotid artery. Shown is the change in one carotid artery but both carotid arteries, and MNP injections in additional mice, showed an almost identical pattern.
Figure 8
Characterization and drug release of DOX-MNPs. (A) Polymer formulations modified with DOX and (B) release profile of DOX from DOX-OE-80 MNPs (data is represented as mean ± SEM, n=3).
Figure 9
Transferrin antibody conjugation to OE-80 MNPs. (A) Antibody conjugation to plain and DOX loaded OE-80 MNPs. (B) Transferrin and BSA binding to OE-80-Ab MNPs indicates proper orientation of transferrin antibody antigen binding sites (data is represented as mean ± SEM, n=3).
Similar articles
- Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting.
Cole AJ, David AE, Wang J, Galbán CJ, Hill HL, Yang VC. Cole AJ, et al. Biomaterials. 2011 Mar;32(8):2183-93. doi: 10.1016/j.biomaterials.2010.11.040. Epub 2010 Dec 21. Biomaterials. 2011. PMID: 21176955 Free PMC article. - Controlled release of doxorubicin from polyethylene glycol functionalized melanin nanoparticles for breast cancer therapy: Part I. Production and drug release performance of the melanin nanoparticles.
Ozlu B, Kabay G, Bocek I, Yilmaz M, Piskin AK, Shim BS, Mutlu M. Ozlu B, et al. Int J Pharm. 2019 Oct 30;570:118613. doi: 10.1016/j.ijpharm.2019.118613. Epub 2019 Aug 12. Int J Pharm. 2019. PMID: 31415880 - Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging.
Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask CA, Labhasetwar V. Jain TK, et al. Biomaterials. 2008 Oct;29(29):4012-21. doi: 10.1016/j.biomaterials.2008.07.004. Epub 2008 Jul 22. Biomaterials. 2008. PMID: 18649936 Free PMC article. - Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K, Sundaresan A, Cheow WS. Hadinoto K, et al. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002. Epub 2013 Jul 17. Eur J Pharm Biopharm. 2013. PMID: 23872180 Review. - Magnetic nanoparticles in MR imaging and drug delivery.
Sun C, Lee JSH, Zhang M. Sun C, et al. Adv Drug Deliv Rev. 2008 Aug 17;60(11):1252-1265. doi: 10.1016/j.addr.2008.03.018. Epub 2008 Apr 10. Adv Drug Deliv Rev. 2008. PMID: 18558452 Free PMC article. Review.
Cited by
- Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles.
Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, Jaggi M, Chauhan SC. Yallapu MM, et al. Biomaterials. 2015 Apr;46:1-12. doi: 10.1016/j.biomaterials.2014.12.045. Epub 2015 Jan 15. Biomaterials. 2015. PMID: 25678111 Free PMC article. - Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.
Guo YY, Huang L, Zhang ZP, Fu DH. Guo YY, et al. Curr Med Sci. 2020 Jun;40(3):463-473. doi: 10.1007/s11596-020-2200-6. Epub 2020 Jul 17. Curr Med Sci. 2020. PMID: 32681251 Review. - Emerging trends in the nanomedicine applications of functionalized magnetic nanoparticles as novel therapies for acute and chronic diseases.
Dash S, Das T, Patel P, Panda PK, Suar M, Verma SK. Dash S, et al. J Nanobiotechnology. 2022 Aug 31;20(1):393. doi: 10.1186/s12951-022-01595-3. J Nanobiotechnology. 2022. PMID: 36045375 Free PMC article. Review. - Dual-function theranostic nanoparticles for drug delivery and medical imaging contrast: perspectives and challenges for use in lung diseases.
Howell M, Wang C, Mahmoud A, Hellermann G, Mohapatra SS, Mohapatra S. Howell M, et al. Drug Deliv Transl Res. 2013 Aug 1;3(4):352-63. doi: 10.1007/s13346-013-0132-4. Drug Deliv Transl Res. 2013. PMID: 23936754 Free PMC article. - Engineered Polyethylene Glycol-Coated Zinc Ferrite Nanoparticles as a Novel Magnetic Resonance Imaging Contrast Agent.
Dabagh S, Haris SA, Ertas YN. Dabagh S, et al. ACS Biomater Sci Eng. 2023 Jul 10;9(7):4138-4148. doi: 10.1021/acsbiomaterials.3c00255. Epub 2023 Jun 13. ACS Biomater Sci Eng. 2023. PMID: 37311018 Free PMC article.
References
- Bulte JW, Kraitchman DL. Monitoring cell therapy using iron oxide MR contrast agents. Curr Pharm Biotechnol. 2004;5:567–584. - PubMed
- Josephson L. Magnetic Nanoparticles for MR Imaging. Springer; US: 2007.
- Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17:484–499. - PubMed
- Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60:6641–6648. - PubMed
- Beaven GH, Chen SH, d’Albis A, Gratzer WB. A spectroscopic study of the haemin--human-serum-albumin system. Eur J Biochem. 1974;41:539–546. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical